XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
  Memory
  Regeneration
  Stroke
  Brain Diseases
  Headache
  Spinal Cord Diseases
  Demyelinating Diseases
   Multiple Sclerosis
  Neurodegenerative Diseases
  Taste
  Trigeminal Neuralgia
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
 
 India
Search

Last Updated: Nov 18, 2006 - 12:32:53 PM

Multiple Sclerosis Channel
subscribe to Multiple Sclerosis newsletter

Latest Research : Neurosciences : Demyelinating Diseases : Multiple Sclerosis

   DISCUSS   |   EMAIL   |   PRINT
Systematic Review Questions Accuracy of MRI in Multiple Sclerosis
Mar 24, 2006 - 1:21:00 PM, Reviewed by: Dr. Priya Saxena

Researchers analysed 29 studies to assess the accuracy of magnetic resonance imaging criteria for the early diagnosis of multiple sclerosis in patients with suspected disease. Each study compared MRI criteria to a reference standard for the diagnosis of multiple sclerosis. The average duration of follow-up ranged from seven months to 14 years.

 
The accuracy of magnetic resonance imaging (MRI) is not sufficient to rule in or rule out a diagnosis of MS with a high degree of certainty, finds a study published online by the BMJ today.

MRI has been adopted in England and Wales by the National Institute for Health and Clinical Excellence (NICE) as part of the recommended criteria for diagnosing multiple sclerosis. Although its accuracy has been assessed, the evidence has not previously been systematically assessed.

Researchers analysed 29 studies to assess the accuracy of magnetic resonance imaging criteria for the early diagnosis of multiple sclerosis in patients with suspected disease. Each study compared MRI criteria to a reference standard for the diagnosis of multiple sclerosis. The average duration of follow-up ranged from seven months to 14 years.

Considerable weaknesses existed in the studies included in the review, and studies with methodological flaws overestimated the diagnostic accuracy of MRI.

Only two studies followed patients for more than 10 years, and these suggested that the role of magnetic resonance imaging either in ruling in or ruling out multiple sclerosis is limited. Patients with a first attack suggestive of MS have around a 60% probability of developing MS, this is increased to between 75 and 84% in those with a positive MRI scan and decreased to between 43 and 57% in those with a negative scan over 10-14 years.

The results suggest that use of magnetic resonance imaging to confirm multiple sclerosis on the basis of a single attack of neurological dysfunction may lead to over-diagnosis and over-treatment.

"There is a real danger of giving patients a serious diagnosis which will affect their lives but may turn out to be incorrect later on," says Penny Whiting.

Dr Jonathan Sterne adds: "Neurologists should discuss potential consequences of false positive and false negative magnetic resonance imaging results with their patients."
 

- British Medical Journal
 

www.bmj.com

 
Subscribe to Multiple Sclerosis Newsletter
E-mail Address:

 



Related Multiple Sclerosis News

Cause of nerve fiber damage in multiple sclerosis identified
Fampridine may hold promise for treating Multiple Sclerosis
CNS can send out signals to invite autoimmune attacks
Natalizumab Re-approved for Relapsing Multiple Sclerosis
Efficacy in relapse rate reduction beyond five years shown for interferon beta 1b in Multiple Sclerosis
Systematic Review Questions Accuracy of MRI in Multiple Sclerosis
Statins could prove useful in treating MS
12.5 kda cystatin may generate first simple test for multiple sclerosis
Fatal flaw in natalizumab, multiple sclerosis drug, trial
Azathioprine reduces new brain inflammatory lesions in MS


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us